ライフサイエンスコーパス: combination antiretroviral therapy

1 ven in the setting of viral suppression with combination antiretroviral therapy.

2 sub-Saharan Africa and 96.8% were receiving combination antiretroviral therapy.

3 vailable for use by HIV-1 and is now used in combination antiretroviral therapy.

4 ation, remarkably with potency equivalent to combination antiretroviral therapy.

5 an age was 47.3 years and 98% were receiving combination antiretroviral therapy.

6 viation [SD], 11.1) years and 97.4% received combination antiretroviral therapy.

7 human immunodeficiency virus (HIV) receiving combination antiretroviral therapy.

8 morbidity among people with HIV/AIDS taking combination antiretroviral therapy.

9 infection can now be readily controlled with combination antiretroviral therapy.

10 ery other week for 8 weeks while maintaining combination antiretroviral therapy.

11 group of HIV-infected individuals undergoing combination antiretroviral therapy.

12 symptomatic HIV-infected subjects undergoing combination antiretroviral therapy.

13 isease, in spite of the notable successes of combination antiretroviral therapy.

14 mong people living with HIV (PLWH) receiving combination antiretroviral therapy.

15 le with those measured in patients receiving combination antiretroviral therapy.

16 y, despite success reducing viral loads with combination antiretroviral therapy.

17 the end of 1995, before the introduction of combination antiretroviral therapy.

18 level, and over time, both before and during combination antiretroviral therapy.

19 t a majority of patients treated with potent combination antiretroviral therapy.

20 ded to address the question of when to begin combination antiretroviral therapy.

21 immunotherapy of HIV-1-infected patients on combination antiretroviral therapy.

22 7 was identified in a patient who had failed combination antiretroviral therapy.

23 V)-infected individuals who are treated with combination antiretroviral therapy.

24 barrier to virus eradication in patients on combination antiretroviral therapy.

25 measles following immune reconstitution with combination antiretroviral therapy.

26 sible in vivo, especially in the presence of combination antiretroviral therapy.

27 K2838232 for the treatment of HIV as part of combination antiretroviral therapy.

28 ts, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy.

29 ral load and were receiving TDF as a part of combination antiretroviral therapy.

30 1 years), 78% of participants were receiving combination antiretroviral therapy, 41% had a CD4(+) cel

31 and immune phenotype and function during pre-combination antiretroviral therapy acute infection and c

32 ug resistance incidence to modern first-line combination antiretroviral therapies against human immun

33 enerally prevents cure of the infection with combination antiretroviral therapy alone.

34 Volunteers with HIV who were undergoing combination antiretroviral therapy and age-matched contr

35 To determine the relationship of combination antiretroviral therapy and bacterial pneumon

36 tively evaluated 16 HIV-infected patients on combination antiretroviral therapy and eight healthy con

37 athy in HIV infection is not eliminated with combination antiretroviral therapy and is possibly linke

38 of infectious HIV-1 persist despite years of combination antiretroviral therapy and make curing HIV-1

39 symptoms resolved completely after starting combination antiretroviral therapy and remain subsided f

40 With the advent of combination antiretroviral therapy and the development o

41 ants with 52 women who did not; 33% received combination antiretroviral therapy, and 65% received mon

42 during a time of widespread availability of combination antiretroviral therapy, and mortality is rea

43 ensive care unit has decreased in the era of combination antiretroviral therapy, and patients are mor

44 ency virus (HIV)-infected (HIV+) patients on combination antiretroviral therapy are living longer but

45 erm clinical trials of BMS-663068 as part of combination antiretroviral therapy are warranted.

46 Early potent combination antiretroviral therapies (ART) for HIV-1 inf

47 NHS subjects who initiated combination antiretroviral therapy (ART) after 1996 were

48 Combination antiretroviral therapy (ART) can suppress pl

49 ients with virological failure of first-line combination antiretroviral therapy (ART) containing the

50 The benefits of combination antiretroviral therapy (ART) for HIV cogniti

51 Combination antiretroviral therapy (ART) for HIV-1 infec

52 Combination antiretroviral therapy (ART) has had a major

53 While the advent of combination antiretroviral therapy (ART) has significant

54 PURPOSE OF REVIEW: Combination antiretroviral therapy (ART) has turned HIV

55 d for patients infected with HIV-1 who start combination antiretroviral therapy (ART) in high-income

56 We find that, as in humans, combination antiretroviral therapy (ART) in humanized (h

57 HIV), but patterns of cancer incidence after combination antiretroviral therapy (ART) initiation rema

58 Combination antiretroviral therapy (ART) is able to supp

59 CD4(+) follicular helper T cells (Tfh) after combination antiretroviral therapy (ART) is essential to

60 Access to combination antiretroviral therapy (ART) is expanding in

61 ROUNDHIV-1 viremia that is not suppressed by combination antiretroviral therapy (ART) is generally at

62 Combination antiretroviral therapy (ART) is highly effec

63 Although lifelong combination antiretroviral therapy (ART) is recommended

64 CD4 count at start of combination antiretroviral therapy (ART) is strongly ass

65 in Africa; whether benefits occur alongside combination antiretroviral therapy (ART) is unclear.

66 We analysed the effect of immediate combination antiretroviral therapy (ART) on viraemia and

67 It remains unclear to what degree combination antiretroviral therapy (ART) protects agains

68 As widespread adoption of potent combination antiretroviral therapy (ART) reaches its ten

69 t the median age of HIV-infected patients on combination antiretroviral therapy (ART) will increase f

70 Combination antiretroviral therapy (ART), also known as

71 factors, including immunosuppression, use of combination antiretroviral therapy (ART), and injecting

72 cohort in Baltimore, we compared receipt of combination antiretroviral therapy (ART), HIV type 1 (HI

73 The bar is high to improve on current combination antiretroviral therapy (ART), now highly eff

74 n, allowing patients to discontinue lifelong combination antiretroviral therapy (ART).

75 een systematically studied during the era of combination antiretroviral therapy (ART).

76 converters and 376 with viral suppression on combination antiretroviral therapy (ART).

77 t challenges to realize the full benefits of combination antiretroviral therapy (ART).

78 eatment experienced (ie, with >/=9 months on combination antiretroviral therapy [ART] and at risk of

79 Access to combination antiretroviral therapy, as well as health re

80 ts, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy at enrollment.

81 ase decreased significantly after 1997, when combination antiretroviral therapy became widely availab

82 the CASCADE collaboration, since 1997, when combination antiretroviral therapy became widely availab

83 tegrated Clinical Systems site who initiated combination antiretroviral therapy between 1 January 200

84 ficiency syndrome (AIDS) after initiation of combination antiretroviral therapy between 1998 and 2012

85 mmunodeficiency virus (HIV) replication with combination antiretroviral therapy, both HIV and chronic

86 We observed that irrespective of combination antiretroviral therapy, both short- and long

87 tively treated by lifelong administration of combination antiretroviral therapy, but an effective vac

88 ential novel therapeutic approach to enhance combination antiretroviral therapy by suppressing hyperi

89 cy virus (SIV) infection model, we show that combination antiretroviral therapy (c-ART) partially rev

90 Although combination antiretroviral therapy can dramatically redu

91 Although potent combination antiretroviral therapy can effectively block

92 Combination antiretroviral therapy can suppress human im

93 Combination antiretroviral therapies (cART) are clearly

94 tablishment and persistence.IMPORTANCE While combination antiretroviral therapies (cART) have transfo

95 ho participated in a clinical trial of early combination antiretroviral therapy (cART) (<6 months fol

96 Combination antiretroviral therapy (cART) administered s

97 Antiretroviral-naive individuals initiating combination antiretroviral therapy (cART) after 1 Januar

98 Present combination antiretroviral therapy (cART) alone does not

99 uction in 20 HIV-infected patients receiving combination antiretroviral therapy (cART) and 2 groups o

100 As a result of effective combination antiretroviral therapy (cART) and advanced s

101 ent of virus that persists despite long-term combination antiretroviral therapy (cART) and can cause

102 mmune activation persist after initiation of combination antiretroviral therapy (cART) and HIV suppre

103 Our objective was to determine the impact of combination antiretroviral therapy (cART) and the degree

104 nitis in patients with AIDS after initiating combination antiretroviral therapy (cART) and the role o

105 n addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy (cART) and to compare

106 kinetics and persistence during suppressive combination antiretroviral therapy (cART) and treatment

107 th treated cryptococcal meningitis who start combination antiretroviral therapy (cART) are at risk of

108 us type 1 (HIV-1)-infected infant started on combination antiretroviral therapy (cART) at 30 hours of

109 Optimization of combination antiretroviral therapy (cART) can impact the

110 ency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing ten

111 Decisions regarding whether to start combination antiretroviral therapy (cART) during primary

112 Patients who start combination antiretroviral therapy (cART) during primary

113 Combination antiretroviral therapy (cART) effectively bl

114 Combination antiretroviral therapy (cART) effectively co

115 Combination antiretroviral therapy (cART) effectively su

116 atient.IMPORTANCE HIV patients who interrupt combination antiretroviral therapy (cART) eventually exp

117 Combination antiretroviral therapy (cART) failure is a m

118 Combination antiretroviral therapy (cART) generally supp

119 Combination antiretroviral therapy (cART) has been shown

120 Combination antiretroviral therapy (cART) has increased

121 s (HIV)-infected children and adolescents on combination antiretroviral therapy (cART) has not been c

122 Combination antiretroviral therapy (cART) has reduced HI

123 Combination antiretroviral therapy (cART) has resulted i

124 The widespread use of combination antiretroviral therapy (cART) has resulted i

125 The advent of combination antiretroviral therapy (cART) has significan

126 wn that NK cells from HIV patients receiving combination antiretroviral therapy (cART) have decreased

127 omen receiving protease inhibitor (PI)-based combination antiretroviral therapy (cART) have lower lev

128 (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral therapy (cART) impacted stead

129 s were quantified during long-term effective combination antiretroviral therapy (cART) in 4 perinatal

130 s type 1 (HIV-1)-infected cells during early combination antiretroviral therapy (cART) in infected in

131 We included HIV+ individuals who started combination antiretroviral therapy (cART) in the Veteran

132 inflammatory syndrome (TB-IRIS) complicates combination antiretroviral therapy (cART) in up to 25% o

133 virologic failure (VF) of initial NVP-based combination antiretroviral therapy (cART) in women with

134 munodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cART) incorporating

135 IV-1 DNA was also assessed after 8 months of combination antiretroviral therapy (cART) initiated in F

136 orrelated directly with the age of effective combination antiretroviral therapy (cART) initiation (P

137 Mortality rates within the first year of combination antiretroviral therapy (cART) initiation are

138 e studies assessing treatment outcomes after combination antiretroviral therapy (cART) initiation in

139 etroviral Treatment (START) study, immediate combination antiretroviral therapy (cART) initiation red

140 e first countries to recommend initiation of combination antiretroviral therapy (cART) irrespective o

141 Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administere

142 We evaluated whether suboptimal adherence to combination antiretroviral therapy (cART) is associated

143 rase strand transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) is associated

144 idual infected cells are present at the time combination antiretroviral therapy (cART) is discontinue

145 e 1 (HIV-1) reservoirs in patients receiving combination antiretroviral therapy (cART) is largely unk

146 Combination antiretroviral therapy (cART) is standard of

147 infection, traditional CKD risk factors, and combination antiretroviral therapy (cART) may all contri

148 Human immunodeficiency virus (HIV) and combination antiretroviral therapy (cART) may both contr

149 Studies analyzing the impact of combination antiretroviral therapy (cART) on cervical in

150 thymic function and CD4 T-cell dynamics and combination antiretroviral therapy (cART) onset were ana

151 the majority of patients receiving long-term combination antiretroviral therapy (cART) present with C

152 infected cells in individuals on suppressive combination antiretroviral therapy (cART) presents a maj

153 Combination antiretroviral therapy (cART) prevents HIV-1

154 fection, and whether immediate initiation of combination antiretroviral therapy (cART) prevents neuro

155 Combination antiretroviral therapy (cART) reduces genita

156 The treatment of AIDS with combination antiretroviral therapy (cART) remains lifelo

157 ed sex act with an HIV-infected person under combination antiretroviral therapy (cART) remains unknow

158 eficiency virus (HIV)-infected children with combination antiretroviral therapy (cART) requires asses

159 Combination antiretroviral therapy (cART) suppresses pla

160 irologically suppressed patients on standard combination antiretroviral therapy (cART) switching to D

161 2% in the UK and 60% in the USA) to initiate combination antiretroviral therapy (cART) than other HIV

162 pecifically restored T cell reactivity after combination antiretroviral therapy (cART) to early infec

163 Early initiation of combination antiretroviral therapy (cART) to human immun

164 After the success of combination antiretroviral therapy (cART) to treat HIV i

165 individuals in clinical studies that include combination antiretroviral therapy (cART) treatment inte

166 Metabolic effects following combination antiretroviral therapy (cART) vary by regime

167 30 SIV-infected pigtailed macaques receiving combination antiretroviral therapy (cART) was conducted.

168 Sustained combination antiretroviral therapy (cART) was defined as

169 esistance testing (GRT) in patients for whom combination antiretroviral therapy (cART) was unsuccessf

170 Patients on combination antiretroviral therapy (cART) were randomize

171 ed to determine if responses to standardized combination antiretroviral therapy (cART) were similar b

172 virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 c

173 ematically recommended for mothers receiving combination antiretroviral therapy (cART) with low viral

174 of HIV-infected individuals despite years of combination antiretroviral therapy (cART) with suppressi

175 eir association with number of vaccinations, combination antiretroviral therapy (cART), and HIV statu

176 ever, owing to better efficacy and safety of combination antiretroviral therapy (cART), and increased

177 btype B, no indication for immediate need of combination antiretroviral therapy (cART), and sufficien

178 ssociated with outcomes of HIV infection and combination antiretroviral therapy (CART), and with neur

179 e case in the setting of early initiation of combination antiretroviral therapy (cART), at high CD4 c

180 L-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL1

181 us (HIV; PLWH) who are receiving suppressive combination antiretroviral therapy (cART), but their pat

182 animals with viremia initially controlled by combination antiretroviral therapy (cART), CPT31 monothe

183 Prior to the introduction of combination antiretroviral therapy (cART), cytopenias we

184 individuals, following the great success of combination antiretroviral therapy (cART), heralds an ex

185 able to HIV-1.SIGNIFICANCE STATEMENT Despite combination antiretroviral therapy (cART), neurocognitiv

186 Before the introduction of combination antiretroviral therapy (cART), patients infe

187 Before the advent of combination antiretroviral therapy (cART), roughly 50% o

188 ected men who have sex with men (MSM) taking combination antiretroviral therapy (cART), the impact of

189 -RNA levels <40 copies per milliliter during combination antiretroviral therapy (cART), the majority

190 Despite immune reconstitution with combination antiretroviral therapy (cART), there was no

191 ce in 7 resource-limited settings (RLSs) for combination antiretroviral therapy (cART)-naive people l

192 t showed significant cognitive impairment in combination antiretroviral therapy (cART)-treated, perin

193 infected and HIV-monoinfected individuals on combination antiretroviral therapy (cART).

194 ich have become more prevalent in the era of combination antiretroviral therapy (cART).

195 reservoir in infected individuals receiving combination antiretroviral therapy (cART).

196 iency virus (HIV)-positive patients starting combination antiretroviral therapy (cART).

197 s after initiation of raltegravir-containing combination antiretroviral therapy (cART).

198 ation of HIV disease in the era of effective combination antiretroviral therapy (cART).

199 ries despite the widespread use of effective combination antiretroviral therapy (cART).

200 (CHER) cohort after 7-8 years of suppressive combination antiretroviral therapy (cART).

201 ically suppressed (VS) individuals receiving combination antiretroviral therapy (cART).

202 be interchangeable components in first-line combination antiretroviral therapy (cART).

203 i sarcoma (KS) incidence has decreased since combination antiretroviral therapy (cART).

204 ells in individuals treated with suppressive combination antiretroviral therapy (cART).

205 ronically infected with HIV-1 that initiated combination antiretroviral therapy (cART).

206 ated cryptococcal meningitis (CM) commencing combination antiretroviral therapy (cART).

207 rm virological suppression during receipt of combination antiretroviral therapy (cART).

208 impairment remains frequent in HIV, despite combination antiretroviral therapy (cART).

209 ) T cells that is only partially reversed by combination antiretroviral therapy (cART).

210 ntrolled viral load and restored immunity on combination antiretroviral therapy (cART).

211 lly-acquired HIV infection (C-PHIV), despite combination antiretroviral therapy (cART).

212 Subjects were viremic on combination antiretroviral therapy (cART).

213 D-L1 (Avelumab) in SIV-infected RM receiving combination antiretroviral therapy (cART).

214 viral gene expression and effectively resist combination antiretroviral therapy (cART).

215 ust have HIV infection that is responsive to combination antiretroviral therapy (cART).

216 We also analyzed effects of initiating combination antiretroviral therapy (cART).

217 trol HIV infection without a requirement for combination antiretroviral therapy (cART).

218 rophic decline is rarely seen in patients on combination antiretroviral therapy (cART); however, neur

219 Thirty-one (39%) of 80 men (59 prescribed combination antiretroviral therapy [cART]) had HIV detec

220 acterial pneumonia resulting from the use of combination antiretroviral therapy containing protease i

221 Combination antiretroviral therapy during primary HIV-1

222 tantially expanded since the introduction of combination antiretroviral therapy during the HIV epidem

223 drome (AIDS), death, or the beginning of the combination antiretroviral therapy era (January 1, 1996)

224 Indeed, in the combination antiretroviral therapy era, the curability o

225 In many patients, combination antiretroviral therapy fails to achieve comp

226 We have utilized combination antiretroviral therapy following human immun

227 14 patients who were receiving highly active combination antiretroviral therapy for > or =116 weeks w

228 st with indinavir for 16 weeks and then with combination antiretroviral therapy for >2 years.

229 Combination antiretroviral therapy for HIV infection imp

230 Randomised, controlled trial data show that combination antiretroviral therapy for HIV-1 infection b

231 The success of combination antiretroviral therapy for HIV-1 infection h

232 acy of raltegravir with efavirenz as part of combination antiretroviral therapy for treatment-naive p

233 for women without advanced disease, lifelong combination antiretroviral therapy for women with advanc

234 ncy virus (HIV) infection with highly active combination antiretroviral therapy has increased surviva

235 r chronic inflammation, and the expansion of combination antiretroviral therapy has led to varied dem

236 of viral loads in people with HIV undergoing combination antiretroviral therapy has mitigated AIDS-re

237 Nonetheless, combination antiretroviral therapy has offered people wi

238 Combination antiretroviral therapy has substantially inc

239 Increased use of combination antiretroviral therapy has substantially red

240 Although combination antiretroviral therapy has substantially red

241 rse of HIV-infected individuals treated with combination antiretroviral therapy in 4 US cities.

242 d durability of response of newly instituted combination antiretroviral therapy in HIV-1-infected chi

243 Some studies suggest that combination antiretroviral therapy in pregnant women wit

244 IV genetic integrity after 9 to 18 months of combination antiretroviral therapy in rhesus macaques st

245 Combination antiretroviral therapy initiated during acut

246 Combination antiretroviral therapy initiated within seve

247 Combination antiretroviral therapy is not available thro

248 mulation suggests that earlier initiation of combination antiretroviral therapy is often favored comp

249 Although combination antiretroviral therapy is potent to block ac

250 Combination antiretroviral therapy is the mainstay of HI

251 been dramatically reduced wherever effective combination antiretroviral therapy is used, there has be

252 s in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is

253 ontrol study, we demonstrate that successful combination antiretroviral therapy (last HIV viral load

254 In recent years, the early initiation of combination antiretroviral therapy leading to virologica

255 Early combination antiretroviral therapy led to a loss of plas

256 The long-term efficacy of combination antiretroviral therapy may relate to augment

257 , CNS penetration effectiveness, duration of combination antiretroviral therapy, medication adherence

258 tients with chronic HIV infection undergoing combination antiretroviral therapy (n=28) and control su

259 9; 30.23%), HIV-infected subjects undergoing combination antiretroviral therapy (n=90; 69.77%) had 47

260 ts are consistent with the notion that early combination antiretroviral therapy of HIV-1-infected inf

261 e men who have sex with men, 78% were taking combination antiretroviral therapy (of whom 86% had an H

262 Concurrent prescription of combination antiretroviral therapy (OR, 0.2) and other a

263 Treg depletion combined with combination antiretroviral therapy provides a novel stra

264 Upon initiation of combination antiretroviral therapy, recovery of cellular

265 d States and Europe confirm that full-course combination antiretroviral therapy reduces rates of moth

266 analyses were performed to identify HIV- and combination antiretroviral therapy-related factors assoc

267 therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monoth

268 The use of combination antiretroviral therapy results in a substant

269 Combination antiretroviral therapy results in metabolic

270 rse transcriptase inhibitor therapy prior to combination antiretroviral therapy, stavudine exposure w

271 eiving durable (median duration, 10.2 years) combination antiretroviral therapy, stratified by age at

272 that in HIV-infected patients on suppressive combination antiretroviral therapy, such host-derived tr

273 ilar in patients virologically suppressed on combination antiretroviral therapy, suggesting that immu

274 nificant decline of plasma HBV DNA load with combination antiretroviral therapy that contained lamivu

275 iciency virus (HIV)-infected patients taking combination antiretroviral therapy that includes HIV pro

276 imited evidence about longer-term effects of combination antiretroviral therapy that includes proteas

277 HIV-1-infected individuals under suppressive combination antiretroviral therapy, that urethral macrop

278 With the introduction of combination antiretroviral therapy, the incidence of HIV

279 Although administered within the context of combination antiretroviral therapy, the infection of bys

280 on is living longer, largely attributable to combination antiretroviral therapy, there is concern abo

281 ecreased after the introduction of effective combination antiretroviral therapy, they became the most

282 With current efforts to provide earlier combination antiretroviral therapy to HIV-infected peopl

283 Administration of combination antiretroviral therapy to human immunodefici

284 n antiretroviral therapy acute infection and combination antiretroviral therapy-treated chronic infec

285 There is no effect of combination antiretroviral therapy use on multiple myelo

286 after adjustments for age, body mass index, combination antiretroviral therapy use, CD4 cell counts,

287 TIs) are recommended components of preferred combination antiretroviral therapies used for the treatm

288 t in the epidemic occurred in 1995-1996 when combination antiretroviral therapy was introduced, effec

289 After adjustment for multiple risk factors, combination antiretroviral therapy was not associated wi

290 nts with latency-reversing agents (LRAs) and combination antiretroviral therapy was proposed as a mea

291 Combination antiretroviral therapy was suspended before

292 Participants with HIV infection receiving combination antiretroviral therapy were randomized equal

293 eline data from 1,053 participants receiving combination antiretroviral therapy who were enrolled in

294 m a HIV-1 elite controller, not treated with combination antiretroviral therapy, who experienced vira

295 Combination antiretroviral therapy with a combination of

296 Early effective combination antiretroviral therapy with prolonged virolo

297 Combination antiretroviral therapy with protease inhibit

298 individuals (n = 17), HIV(+) individuals on combination antiretroviral therapy with viral loads belo

299 HIV, especially for individuals on long-term combination antiretroviral therapy with well controlled

300 een functionally cured of HIV by being given combination antiretroviral therapy within hours of birth